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ABSTRACT 
 
We report the 1st case of severe, symptomatic hypocalcemia after denosumab (RANKL 
inhibitor) treatment in a peritoneal dialysis patient with secondary hyperparathyroidism 
and osteoporosis. A 58-year-old Caucasian female has been receiving chronic 
ambulatory peritoneal dialysis for four years secondary to polycystic kidney disease. 
Laboratory studies revealed: albumin-corrected calcium 9.0 mg/dL, phosphorus 5 mg/dL, 
alkaline phosphatase (ALP) 58 U/L [normal, 40-105], albumin 3.4 gm/dL [normal, 3.6-5.4] 
and intact parathyroid hormone (PTH) 315 pg/mL [normal, 40-72]. Marked osteoporosis 
was noted on the DXA scan, preventing her from renal transplantation considerations. 
She had failed conventional medical treatment, including per os calcium, monthly 
ergocalciferol (50,000 units/month), activated vitamin-D analog (doxercalciferol) and 
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renal-failure adjusted alendronate (70 mg twice a month).  She was started on 
subcutaneous denosumab 60 mg every 6 months. After her first dose, she developed a 
progressive drop of calcium, phosphorus, bicarbonate and magnesium, in spite of 
massive escalation of doxercalciferol and calcium supplementation.  Hypocalcemia 
nadired at 6.3 mg/dL with symptomatic tetany, requiring a brief hospitalization 
approximately 7 weeks after denosumab treatment. Her elevated PTH rose further 
transiently (647 pg/mL), along with ALP (123 U/L). Bone-mineral parameters normalized 
approximately 3 months after denosumab administration. The observed phenomenon 
resembled the phenotype of “hungry bone syndrome” observed after surgical 
parathyroidectomy.  
Conclusion: Treatment decisions based on bone densitometry results alone are not 
transposable between patients with or without end-stage renal disease. Denosumab may 
lead to critical hypocalcemia in dialysis patients and further aggravate existing secondary 
hyperparathyroidism. 
  
 
Keywords: Denosumab; end-stage renal disease; hungry bone syndrome; hypocalcemia; 
osteoporosis; RANK ligand inhibitor; tetany. 
 
1. INTRODUCTION 
 
Bisphosphonates bind bone minerals and are absorbed by mature osteoclasts, inducing 
osteoclast apoptosis and suppressing resorption [1,2]. Due to the potential renal toxicity of 
bisphosphonates, there has been some interest in the use of denosumab, a receptor 
activator of nuclear factor (NF-κB) ligand (RANKL) inhibitor for treatment of osteoporosis in 
patients with renal impairment. Until recently, denosumab, as per the manufacturer's 
instructions, did not require dosage adjustments for renal impairment [3]. Published 
experience of the use of denosumab in end-stage renal disease (ESRD) is, however, very 
scant. One preliminary study of 8 hemodialysis patients [4] and another case report have 
raised concerns about severe hypocalcemia in hemodialysis patients [5]. We report the 1st 
case of severe symptomatic hypocalcemia secondary to denosumab in a peritoneal dialysis-
dependent patient with controlled secondary hyperparathyroidism. 
 
2. CASE STUDY 
 
Our index patient was a 58-year-old Caucasian female with end-stage renal disease (ESRD) 
secondary to polycystic kidney, who had been on chronic ambulatory peritoneal dialysis 
(CAPD) for 4 years and doing well on renal replacement therapy, except for a progressive 
height loss. A dual-energy x-ray absorptiometry (DXA) scan was obtained in August of 2011, 
revealing significant osteoporosis (Table. 2). She denied a prior history of osteoporosis or 
any fracture. Except for continued tobacco abuse, she denied risk factors such as 
glucocorticoid use, seizure medications or a family history of osteoporosis. She had been on 
a vitamin D supplement 50,000 International Units once a month and was previously on 
over-the counter calcium-carbonate as phosphorus binder; however, she developed 
transient hypercalcemia and calcium carbonate was discontinued. She was placed on 
alendronate (Fosamax®) which she had been taking without any difficulty.  
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Table 1. Changes of bone-mineral metabolism parameters after denosumab administration 
 
Date (Days 
Since 
Denosumab 
dosage) 
04/10/12  
(-73) 
06/21/12  
(-1) 
07/26/12 
(34) 
08/14/12 
(53) 
08/23/12 
(62) 
09/11/12 
(81) 
10/09/12 
(109) 
11/01/12 
(132) 
12/06/12 
(167) 
Ref. Range 
Calcium 9.2 8.5 6.9 6.6 9.6 10.0 8.9 9.7 9.3 8.2-10.1 
mg /dL 
Calcium 
(Adjusted for 
albumin) 
9.5 9.0 7.4 7.0  10.6 9.5 10.3 9.8 8.2-10.1 
mg/dL 
Phosphorus 5.0 5.0 3.4 4.6 2.6 4.2 5.7 7.5 7.6 2.5-5.0 mg/dL 
Alkaline 
Phosphatase 
58  85 123  122 62 50 43 40-105 IU/L 
iPTH 315  647    117   14-72 pg/mL 
 
Table 2. DXA results summary (August 2011) 
 
Region Area (cm2) BMC (g) BMD (g/cm2) T-score Z-score 
Neck 5.27 2.53 0.480 -3.3 -2.2 
Total 32.05 20.68 0.645 -2.4 -1.7 
L1 13.38 8.79 0.657 -3.0 -2.0 
L2 14.24 9.48 0.666 -3.3 -2.1 
L3 16.94 12.42 0.734 -3.2 -2.0 
L4 16.09 10.52 0.654 -3.7 -2.4 
Total 60.65 41.22 0.680 -3.3 -2.1 
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However, she noted further height loss over the ensuing months and was also rejected by 
the renal transplant team, citing her severe osteoporosis ruling out considerations of renal 
transplant eligibility. Co-morbid issues associated with her ESRD included secondary 
hyperparathyroidism and hyperphosphatemia, renal anemia with functional iron deficiency 
and chronic hypoalbuminemia and hypokalemia associated with peritoneal dialysis. Other 
co-morbidities included a prior cerebrovascular accident with no residual deficit, well-
controlled hypertension, allergic rhinitis, chronic anxiety, history of colonic polyps and 
arteriovenous malformations and vitamin-D deficiency requiring replacement. For chronic 
metabolic acidosis, she was taking potassium-citrate on a long-term basis. 
 
 
 
Fig. 1. Calcium, adjusted calcium and phosphorus changes after denosumab 
administration. 
Denosumab initiated on day '0', alendronate discontinued on day '-31' (31 days prior to denosumab 
initiation) 
 
In terms of ESRD, she had done reasonably well on a CAPD regimen of 2 liters x 4 
exchanges with 1.5% dextrose solution.  Return volumes were always satisfactory, resulting 
in a net ultrafiltration of 300-800 mL per exchange.  Comprehensive dialysis flow sheets 
revealed excellent Kt/V’s between 2.2-2.8 per week but a progressive loss of creatinine 
clearance over the years, most recently 52 L/week/1.73 m2. Her residual urine output was 
very limited (30-40 mL/day) and contributed little to her overall clearance. 
 
Laboratory studies (Table. 1) at baseline revealed: albumin-corrected calcium 9.0 mg/dL, 
phosphorus 5 mg/dL, alkaline phosphatase (ALP) 58 U/L [normal, 40-105], albumin 3.4 
gm/dL [normal, 3.6-5.4] and intact parathyroid hormone (PTH) 315 pg/mL [normal, 40-72]. 
The 25-hydroxy vitamin-D level was normal at 31.3 ng/ml [normal, 20-100], 1,25 di-hydroxy 
Vitamin D was 25 pg/mL [normal, 18-78].  Four years earlier, serum protein and urine 
electrophoresis revealed only non-selective proteinuria and no evidence of multiple 
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myeloma. Baseline medications included doxercalciferol (2.5 mcg twice weekly), sevelamer 
(2400 mg TID with meals and 1600 mg at bedtime), ergocalciferol (50,000 IU once a month) 
and alendronate (70 mg twice a month). Rheumatology consultants recommended to 
discontinue her alendronate and to start denosumab every 6 months. The first dose was 
given on 06/22/12 along with instructions to take daily over-the-counter 500 mg calcium 
carbonate. After her first dose, she developed a progressive drop of calcium (Fig. 1), 
phosphorus, bicarbonate and magnesium, in spite of massive escalation of bioactive 
vitamin-D analog and calcium supplementation (calcium acetate 2001 mg (elemental 
calcium 507 mg) three times daily, calcium carbonate 2250 mg at bedtime (elemental 
calcium 898.2 mg), doxercalciferol 2.5 mcg daily) and increased calcium content of 
peritoneal fluid to 3.0 mEq/L. With progressive hypocalcemia, calcium dropped to 6.3 mg/dL, 
with symptomatic tetany requiring a brief hospitalization locally approximately 7 weeks after 
denosumab treatment. As expected, PTH rose transiently during this period (647 pg/mL), 
along with ALP (123 U/L). After a short period of transient hypercalcemia, bone-mineral 
parameters, including calcium, phosphorus and ALP normalized approximately 3 months 
after denosumab administration. Incidentally, she had an episode of back pain after sudden 
jerking movements of her extremities and torso in July 2012 leading to an x-ray investigation 
(8/14/12) showing right superior and inferior pubic rami fractures which demonstrated 
healing on follow-up X-rays. 
 
3. DISCUSSION 
 
Denosumab is the first Federal Drug Administration (FDA) approved RANK Ligand inhibitor. 
As Prolia® (Thousand Oaks, CA, USA), it was initially approved in June 2010 for treatment 
of postmenopausal osteoporosis with high risk of fractures. This approval was based on a 
three-year, randomized, double-blind, placebo-controlled trial of 7,808 osteoporotic 
postmenopausal women ages 60 to 91 years (Fracture Reduction Evaluation of Denosumab 
in Osteoporosis Every 6 Months or FREEDOM Study), in which denosumab reduced the 
incidence of vertebral, non-vertebral, and hip fractures [6]. Indications since then have been 
expanded to include increasing bone mass in patients at high risk for fracture receiving 
androgen deprivation therapy for non-metastatic prostate cancer or adjuvant aromatase 
inhibitor therapy for breast cancer (Approval September 2011), and to increase bone mass 
in men with osteoporosis at high risk for fracture (Approval September 2012). As Xgeva®, 
Denosumab is also approved for prevention of skeletal-related events in patients with bone 
metastases from solid tumors with the exception of Multiple Myeloma (Approval November 
2010). 
 
Osteoclast differentiation factor, also called receptor activator of nuclear factor (NF-κB) 
ligand (RANKL), stimulates the differentiation of osteoclast progenitors into osteoclasts. 
Osteoprotegerin acts as a natural soluble decoy receptor to bind RANKL and thus, reducing 
RANKL binding to RANK and reducing bone resorption. Denosumab is a full length human 
monoclonal antibody of IgG2 subtype mimicking the action of natural osteoprotegerin by 
binding to and inhibiting RANKL. It exhibits a nonlinear, dose dependent pharmacokinetics 
after subcutaneous injection, with levels peaking in 7-21 days [7]. As expected for an IgG 
antibody, it is not cleared by the kidneys and, therefore, does not require dosage 
adjustments for renal impairment [4]. Denosumab administration results in rapid and 
sustained decrease for markers of bone resorption; in one study, an 85% reduction in serum 
C-telopeptide of type I collagen (a bone resorption marker reflecting osteoclast activity) was 
seen in 3 days, with a peak reduction in one month [3]. Therefore, this potent and long 
lasting effect on bone remodeling raises the concerns for hypocalcemia. This was clinically 
noted in the FREEDOM trial in which within one month, 1.7% of subjects from the drug arm 
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experienced calcium values below 8.5 mg/dl as opposed to 0.4% in the placebo arm [6,8]. It 
should be noted that in the FREEDOM Trial, only 73 women had a calculated creatinine 
clearance 15 to 29 mL/min and none had end-stage renal dysfunction (< 15 mL/min) and, 
therefore, it was underpowered to study the hypocalcemic effects of denosumab in severe 
CKD or terminal renal failure [9]. In patients with normal kidney function, nadir in serum 
calcium is noted on day 10 [3]. This hypocalcemic effect appears to be more pronounced in 
patients with renal insufficiency. In the FREEDOM Extension study of 4,550 subjects, a more 
marked reduction in serum calcium was noted in subjects with renal insufficiency: -5.5% 
reduction in mean serum calcium in subjects with creatinine clearance < 30 mL/min vs. -
3.1% in subjects with creatinine clearance ≥ 30 mL/min at approximately day 10 [3,10].  In 
another study of 55 patients with various degrees of renal impairment, severe and persistent 
hypocalcemia was noted in subjects with severe CKD (GFR <30 mL/min/1.73 m2), which 
was especially profound with kidney failure requiring hemodialysis. 5 out of 8 dialysis 
dependent patient developed hypocalcemia (serum calcium < 8 mg/dL) and calcium dropped 
below 7.5 mg/dL in 2 of them [4]. Additionally, McCormick et al. also recently reported a case 
of severe hypocalcemia with denosumab in a hemodialysis patient [5]. Interestingly, a recent 
case report mentioned successful treatment of immobilization-related hypercalcemia with 
denosumab in a patient with advanced renal insufficiency [11]. In a boy with fibrous 
dysplasia, denosumab did not impair healing of a femoral fracture that occurred while on 
treatment during which, similar to our case presented here, secondary hyperparathyroidism 
developed [12]. 
 
Clinical experience thus far suggests that denosumab can result in a rapid and sustained 
reduction in serum calcium in the presence of severe renal insufficiency or renal failure. This 
effect may be more pronounced in patients with a history of secondary hyperparathyroidism, 
perhaps as a function of a larger osteoblast mass in these patients. Inhibition of osteoclastic 
activity by denosumab may result in excess unopposed osteoblastic activity and resultant 
severe sustained hypocalcemia, analogous to what we observe as “hungry bone syndrome” 
after surgical parathyroidectomy [13,14]. This sustained hypocalcemia can also (further) 
elevate PTH and aggravate existing secondary hyperparathyroidism. Of note, our patient 
with existing secondary hyperparathyroidism had previously been treated with a 
bisphosphonate (alendronate) before denosumab had been administered while 1,25-
dihydroxy vitamin D and 25-OH vitamin D levels were within normal range, possibly 
suggesting an additive effect of both antiresorptive agents. Our patient had PTH in the target 
range, normal calcium and vitamin D levels at baseline, and was already receiving calcium 
supplementation and activated vitamin D analog (doxercalciferol) for secondary 
hyperparathyroidism. While hypocalcemia was expected, the magnitude and the length of 
the process were certainly surprising to us. Of note, Health Canada placed a hypocalcemia 
alert on denosumab in June of 2012 (http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-
avis/public/_2012/xgeva_pc-cp-eng.php). Additionally, the manufacturer (Amgen) also 
issued additional warning in the US in September of 2012 
(http://www.proliahcp.com/pdf/dear_healthcare_professional_letter.pdf), including indicating 
the risk of severe hypocalcemia.  
 
Our patient was treated for presumed osteoporosis with denosumab per recommendation by 
the Rheumatologist on the basis of an abnormal DXA scan. As opposed to non-CKD 
patients in whom osteoporosis is the predominant cause of bone disease and fractures, 
renal osteodystophy is a heterogenous disorder. Standard imaging diagnostic criteria for 
osteopenia/osteoporosis developed for use with the general population are sometimes 
extrapolated to patients with advanced CKD with less than satisfactory results. Bone mineral 
density (BMD) obtained from the widely used test DXA scan is a prime example. A low bone 
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density noticed on DXA is routinely labeled as osteopenia/osteoporosis based upon Word 
Health Organization (WHO) definitions, but it may be too simple of a label for a patient with 
advanced CKD [15,16].  DXA scan is a two-dimensional projection that indirectly represents 
BMD through X-ray absorption and as three-dimensional structures are invisible, this 
imaging modality cannot distinguish between a fully mineralized porous bone and an 
undermineralized bone with less porosity. Further, DXA scans have not been validated to be 
a reliable test in dialysis related, or secondary hyperparathyroidism-related bone disease 
[17]. Disease spectrum in these patients can vary from a high turnover disease with true 
secondary hyperparathyroidism to a low turnover states with adynamic bone disease and the 
correct diagnosis in the absence of a bone biopsy remains a challenge. Adynamic bone 
diseases is of particular concern as the standard antiresorptive treatment prescribed for 
osteoporosis treatment (bisphosphonates, denosumab) has theoretical potential to 
exacerbate adynamic bone disease. Even an increase in measured bone density may not 
result in reduction in fracture risk if the bone is of poor quality. Because of this complex 
interplay, not all CKD patients are likely to benefit from the standard antiresorptive treatment 
prescribed for the presumed diagnosis of osteopenia/osteoporosis based upon WHO 
definition and indeed studies have demonstrated this heterogeneity [18,19]. 
 
Currently, we do not have any current guidelines about e.g. adjusting the initial dose of 
denosumab during the first treatments.  Denosumab should be best avoided, for the time 
being, in patients with ESRD and significant secondary hyperparathyroidism until further 
clinical experience is been gathered on how to prevent or manage hypocalcemia. Even 
when patients are adequately repleted on vitamin-D (normal 25-hydroxy vitamin-D and 1,25 
di-hydroxy vitamin D levels), large doses of calcium supplements are required. We would 
like to advocate the use of IV calcium gluconate, supraphysiologic dialysate calcium 
concentration, and high doses of oral calcium supplements (6-12 grams per day) together 
with Vitamin D repletion and reducing denosumab dose under these circumstances. 
Nonetheless, a blank elimination of this medication from the therapeutic armamentarium 
may not be the best long-term policy after all; if so doing, we would never expose patients to 
surgical parathyroidectomy for the fear of hypocalcemia and hungry bone syndrome. The 
very fact that our patient developed such severe degree of hypocalcemia may serve as a 
predictor of an excellent potential for bone mineralization and successful future outcomes for 
bone integrity. We also sorely need bone histology data in these patients, where local 
expertise on obtaining and interpreting bone biopsy specimens are available. Whether 
denosumab has any role in treating hypercalcemia in dialysis patients, beyond cancer-
induced hypercalcemia [20], is unclear at this time. Potentially, a patient with osteoporosis 
and hypercalcemia may be the ideal candidate, but this issue is clearly not well studied or 
understood at this point. 
 
4. CONCLUSION 
   
Treatment decisions based on bone densitometry results alone (rather than bone biopsy) are 
not transposable between patients with or without end-stage renal disease. An antiresorptive 
agent such as denosumab may lead to critical and prolonged hypocalcemia in dialysis 
patients as observed in this case and further aggravate existing secondary 
hyperparathyroidism.  Additional research is needed to identify the highest risk patients and 
effective strategies to minimize this serious side effect.  
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Written informed consent was obtained from the patient for publication of this case report, 
who had an opportunity to read and review this paper and received a copy of it. 
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upon request. 
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